Scientific Industries (SCND) Q4 2024 earnings summary

Executive summary

• Fiscal 2024 marked a transformative year with new board members, operational streamlining, and product launches.

• Operating expenses were reduced by nearly $3 million, and cash used in operations was cut by $2.5 million.

• The VIVID Workstation, a new pharmacy automation product, was launched and received strong market interest.

• The bioprocessing segment launched key products and entered 2025 with a robust pipeline.

Financial highlights

• Benchtop laboratory equipment sales declined 3.6% year-over-year, reflecting industry challenges.

• Bioprocessing segment sales grew 24% compared to 2023, with stable gross margins and a $1 million reduction in net loss.

• Q4 2024 bioprocessing sales grew 23% quarter-over-quarter and 31% year-over-year.

• Operating expenses in Q4 dropped 11% year-over-year; full-year cost reduction totaled $800,000.

• The DOTS platform contributed about 50% of bioprocessing revenues since its May 2024 launch.

Outlook and guidance

• Anticipates strong growth in 2025, with expansion of the TORBAL business and launch of a machine learning model for pill counting.

• Bioprocessing segment expects to capitalize on a projected market rebound by 2026, driven by digitalization and demand for real-time data.

• Early 2025 may remain challenging, but a robust pipeline and market recovery are expected.